XML 78 R65.htm IDEA: XBRL DOCUMENT
v3.26.1

License Agreements - CAR-T Products License (Details) - License And Development Agreement With TDT | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2018 USD ($) Milestone | Dec. 31, 2018 USD ($)
CAR-T products and CAR-T Diagnostics |  |
License Agreements |  |
Upfront payment of license agreement fees |  | $ 5,000,000
Annual maintenance fees | $ 500,000 |
Unpaid annual maintenance fees, short term debt interest rate (%) | 1.50% |
Number of developmental and regulatory milestone payments for first product development | Milestone | 4 |
Maximum aggregate milestone commitment fund for first product development | $ 15,000,000 |
Number of developmental and regulatory milestone payments for each additional product development | Milestone | 4 |
Maximum milestone commitment fund for each additional product development | $ 7,500,000 |
CAR-T products and CAR-T Diagnostics | Net sales of period from first commercial sale until patent expires | Minimum |  |
License Agreements |  |
Percentage of royalty fees (%) | 10.00% |
CAR-T products and CAR-T Diagnostics | Net sales of period from first commercial sale until patent expires | Maximum |  |
License Agreements |  |
Percentage of royalty fees (%) | 15.00% |
CAR-T products and CAR-T Diagnostics | 10 years from first commercial sale of products |  |
License Agreements |  |
Number of years from first commercial sale of products (in years) | 10 years |
CAR-T products and CAR-T Diagnostics | 10 years from first commercial sale of products | Minimum |  |
License Agreements |  |
Percentage of royalty fees (%) | 5.00% |
CAR-T products and CAR-T Diagnostics | 10 years from first commercial sale of products | Maximum |  |
License Agreements |  |
Percentage of royalty fees (%) | 9.00% |
Phase II and Phase III clinical trials of CAR-T Product | Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product |  |
License Agreements |  |
Amount of fund obligated to advance for each phase | $ 20,000,000 |

X
- Definition Amount of maximum aggregate milestone commitment fund for first product development. + References No definition available. + Details
Name: | limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of maximum milestone commitment fund for each additional product development. + References No definition available. + Details
Name: | limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of license milestone commitment fund obligated to pay for each phase. + References No definition available. + Details
Name: | limn_LicenseMilestoneCommitmentFundPayableForEachPhase
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of milestone developmental and regulatory milestone payments for each additional product development. + References No definition available. + Details
Name: | limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment
Namespace Prefix: | limn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of milestone developmental and regulatory milestone payments for first product development. + References No definition available. + Details
Name: | limn_NumberOfMilestonePaymentsForFirstProductDevelopment
Namespace Prefix: | limn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic. + References No definition available. + Details
Name: | limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts
Namespace Prefix: | limn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty fees + References No definition available. + Details
Name: | limn_RoyaltyFeesPercentage
Namespace Prefix: | limn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees. + References No definition available. + Details
Name: | limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate
Namespace Prefix: | limn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of upfront payment of license agreement fee. + References No definition available. + Details
Name: | limn_UpfrontPaymentOfLicenseAgreementFees
Namespace Prefix: | limn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost of maintenance incurred and directly related to good produced and service rendered. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_CostMaintenance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=limn_LicenseAndDevelopmentAgreementWithTdtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |